News & Updates

People living with HIV-1 (PLWH) who discontinued traditional non-nucleoside reverse transcriptase inhibitor (NNRTI)- and boosted integrase strand transfer inhibitor (INSTI)-based regimens have maintained viral suppression following their switch to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF), as shown by the 144-week open-label results from the SPRINT* post-study presented at ESCMID Global 2026.

A payer-perspective study from the University of Hong Kong (HKU) indicates that single-dose baloxavir is a more cost-effective outpatient treatment option for seasonal influenza than oseltamivir, despite baloxavir’s higher acquisition cost.

An open-label extension (OLE) study demonstrates the long-term safety, tolerability, and efficacy of atogepant for migraine prevention.

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown.